Analysts Offer Predictions for RCKT FY2025 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Cantor Fitzgerald issued their FY2025 EPS estimates for Rocket Pharmaceuticals in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the biotechnology company will post earnings per share of ($3.20) for the year. Cantor Fitzgerald has a “Overweight” rating and a $65.00 price target on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share.

A number of other research analysts also recently commented on the company. Leerink Partners dropped their price target on Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating for the company in a research note on Tuesday, November 19th. Wedbush began coverage on shares of Rocket Pharmaceuticals in a report on Monday, December 30th. They set an “outperform” rating and a $32.00 price target for the company. Canaccord Genuity Group reissued a “buy” rating and issued a $39.00 price objective on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Needham & Company LLC restated a “buy” rating and set a $52.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Finally, Scotiabank initiated coverage on Rocket Pharmaceuticals in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $50.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $47.27.

Rocket Pharmaceuticals Price Performance

Shares of NASDAQ RCKT opened at $10.71 on Thursday. The business has a fifty day moving average price of $12.32 and a two-hundred day moving average price of $16.81. The stock has a market capitalization of $976.32 million, a PE ratio of -3.89 and a beta of 1.01. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. Rocket Pharmaceuticals has a fifty-two week low of $10.07 and a fifty-two week high of $31.47.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.07.

Insider Buying and Selling at Rocket Pharmaceuticals

In related news, CEO Gaurav Shah sold 11,091 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $13.05, for a total value of $144,737.55. Following the sale, the chief executive officer now owns 707,328 shares of the company’s stock, valued at $9,230,630.40. The trade was a 1.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 13,490 shares of company stock worth $176,045. 28.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Rocket Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 582 shares during the period. KBC Group NV boosted its holdings in Rocket Pharmaceuticals by 159.6% in the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 3,366 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Rocket Pharmaceuticals during the 3rd quarter valued at approximately $108,000. SG Americas Securities LLC bought a new position in Rocket Pharmaceuticals during the 3rd quarter worth approximately $113,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Rocket Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 19,329 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 1,824 shares during the period. 98.39% of the stock is owned by institutional investors and hedge funds.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.